Equity in Cancer Care: Pathways, Protocols, and Guidelines

Authors:
Jessica K. DeMartino From the National Comprehensive Cancer Network, Fort Washington, Pennsylvania.

Search for other papers by Jessica K. DeMartino in
Current site
Google Scholar
PubMed
Close
 PhD
and
Jonathan K. Larsen From the National Comprehensive Cancer Network, Fort Washington, Pennsylvania.

Search for other papers by Jonathan K. Larsen in
Current site
Google Scholar
PubMed
Close
 MPP
Restricted access

The quality of patient care varies based on numerous factors, such as health care setting, geographic location, access to medications, insurance coverage, and treatment protocols. Recently, the issue of whether use of clinical pathways can reduce costs and inappropriate variability in care has been the subject of much debate. As clinical treatment guidelines and pathways are increasingly deployed in oncology practice, they have a growing impact on the quality of treatment and how it is delivered. To fulfill the current need to discuss the use of pathways and clinical treatment guidelines in oncology and to address how patient care is impacted by their use, the National Comprehensive Cancer Network convened the NCCN Oncology Policy Summit: Equity in Cancer Care–Pathways, Protocols, and Guidelines. The summit was a forum to discuss the use and implementation of pathways, including how much flexibility pathways should allow in care, pathways’ impact on public and private health insurance benefit design, what data is used to select pathway regimens and protocols, and ultimately what impact pathways may have on variation in care. The use and implementation of clinical treatment guidelines in practice was also explored from a variety of perspectives.

Correspondence: Jessica K. DeMartino, PhD, National Comprehensive Cancer Network, 275 Commerce Drive, Suite 300, Fort Washington, PA 19034. E-mail: demartino@nccn.org

The authors have disclosed that they have no financial interests, arrangements, or affiliations with the manufacturers of any products discussed in this article or their competitors; they are employees of the National Comprehensive Cancer Network.

  • Collapse
  • Expand
  • 1.

    Wennberg JE, Freeman JL, Culp WJ. Are hospital services rationed in New Haven or over-utilized in Boston? Lancet 1987;11851188.

  • 2.

    Morden NE, Chang CH, Jacobson JO et al.. End-of-life care for medicare beneficiaries with cancer is highly intensive overall and varies widely. Health Affairs 2012;4:786796.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Onega T, Duell EJ, Shi X et al.. Geographic access to cancer care in the U.S. Cancer 2008;112:909918.

  • 4.

    Winn RJ, McClure J. The NCCN Clinical Practice Guidelines: a primer for users. J Natl Compr Cancer Netw 2003;1:513.

  • 5.

    CardinalHealth Web site. Available at: https://www.p4pathways.com/. Accessed July 27, 2012.

  • 6.

    New Century Health Web site. Available at: http://www.newcenturyhealth.com/about.html. Accessed July 27, 2012.

  • 7.

    D3 Oncology Solutions Web site. Available at: http://www.d3onc.com/pathways/. Accessed July 27, 2012.

  • 8.

    Farina K. Forging a pathway to quality cancer care. Am J Manag Care 2012;18:SP116118.

  • 9.

    eviti Web site. Available at: http://www.eviti.com/. Accessed July 27, 2012.

  • 10.

    Level I Pathways. The US Oncology Network Web site. Available at: http://www.usoncology.com/cancercareadvocates/AdvancingCancerCare/DeliverHigh-QualityCare/LevelIPathways. Accessed July 27, 2012.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Feinberg BA, Lang J, Grzegorczyk J et al.. Implementation of cancer clinical pathways: a successful model of collaboration between payers and providers. Am J Manag Care 2012;18:e194e199.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Butcher L. State oncology groups advance clinical pathways. Oncology Times 2011;33:1416.

  • 13.

    Mariotto AB, Yabroff KR, Shao Y et al.. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst 2011;103:117128.

  • 14.

    Barr TR, Towle EL. National oncology practice benchmark, 2011 report on 2010 data. J Oncol Pract 2011;7(6 Suppl):67S82S.

  • 15.

    Neubauer MA, Hoverman JR, Kolodziej M et al.. Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting. J Oncol Pract 2010;6:1218.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Hoverman JR, Cartwright TH, Patt DA et al.. Pathways, outcomes, and costs in colon cancer: retrospective evaluations in two distinct databases. J Oncol Pract 2011;7(3 Suppl):52S59S.

    • PubMed
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 3994 286 23
PDF Downloads 972 188 14
EPUB Downloads 0 0 0